Grace Halsey

3 days ago | patientcareonline.com | Grace Halsey

A large-scale implementation study of digital cognitive assessments in primary care found that clinicians completed screenings in only 11% of eligible patient encounters, despite relatively high patient acceptance rates, raising questions about the feasibility of widespread dementia screening in busy primary care settings.

3 days ago | patientcareonline.com | Grace Halsey

A study of nearly 2,000 women in midlife reveals that social determinants of health (SDOH) significantly influence access to menopausal hormone therapy, with women who have higher education, stable partnerships, and healthier dietary habits more likely to receive treatment for menopause symptoms, the authors reported.

3 days ago | patientcareonline.com | Grace Halsey

Guardant Health announced June 2 that the FDA has granted Breakthrough Device designation to the company's Shield multi-cancer detection (MCD) test, advancing the potential for a single, blood-based screening tool for multiple solid tumor types to be deployed in clinical practice.1 The designation was awarded based on the test’s potential to improve early cancer detection in asymptomatic adults aged 45 or older at average risk for cancer, including bladder, colorectal, esophageal, gastric,...

4 days ago | patientcareonline.com | Grace Halsey

A large diagnostic accuracy study to evaluate the performance of a circulating tumor DNA (ctDNA) blood test for colorectal cancer (CRC) found the test had a sensitivity of 79.2% for CRC and specificity of 91.5% for advanced colorectal neoplasia in a diverse cohort of asymptomatic adults at average risk for the disease.

4 days ago | patientcareonline.com | Grace Halsey

Nasus Pharma’s phase 2 clinical study of its investigational intranasal epinephrine powder, FMXIN002 (aka NS002), has been published in The Journal of Allergy and Clinical Immunology: Global, according to a June 3 company announcement. The study, conducted at Hadassah Medical Center in Jerusalem, compared the bioequivalence of 2 doses of FMXIN002 (3.6 mg and 4.0 mg) to the standard 0.3 mg intramuscular (IM) epinephrine autoinjector in 12 healthy adult volunteers.